Key players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).
This report "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020", provides a detailed overview of the market for ketamine in the U.S., current market trends, supply chain, competitive analysis, market entry strategies, and revenue forecast.
Browse 42 market data tables and 28 figures spread through 114 pages and in-depth TOC on “U.S. General Anesthesia Drugs Market"
www.marketsandmarkets.com/Market-…t-713.html
The U.S. general anesthesia drugs market is poised to reach ~ USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.
Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are driving the growth of the U.S. general anesthesia drugs market.
However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.
Download Free Sample Copy of Report @ www.marketsandmarkets.com/pdfdown…asp?id=713
The market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium.
Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.
You can also speak to our Research Analyst for more Information about Report @ www.marketsandmarkets.com/speakto…asp?id=713
On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational.
The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015.
Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.
Major players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).
For more information:
News From
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w ...